{"url_path":"/sec/vvos/8-k/2026-08-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-037173-index.html","accession_number":"0001493152-26-037173","cik":"0001716166","ticker":"VVOS","issuer_name":"Vivos Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-037173-index.html","primary_entity_key":"0001716166","primary_entity_name":"Vivos Therapeutics, Inc."},"word_count":127,"has_tables":true,"body_markdown":"**Item\n7.01. Regulation FD Disclosure.**\n\n \n\nOn\nAugust 5, 2026, Vivos Therapeutics, Inc. issued a press release announcing the issuance of its new US Patent No. 12,697,190.\n\n \n\nA\ncopy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe\ninformation furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed”\nfor purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section,\nand shall not be deemed incorporated by reference into any filing under the Securities Act, or the Exchange Act, as amended, except as\nexpressly set forth by specific reference in such filing."}